Changes to legislation: There are currently no known outstanding effects for the The Human Medicines Regulations 2012, Paragraph 9. (See end of Document for details)

# SCHEDULES

### [<sup>F1</sup>SCHEDULE 12A

Further provision as to the performance of pharmacovigilance activities

# F1 Sch. 12A inserted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), reg. 1, Sch. 6 (as amended by S.I. 2019/1385, reg. 1, Sch. 1 para. 9 and S.I. 2020/1488, reg. 1, Sch. 2 para. 192); 2020 c. 1, Sch. 5 para. 1(1)

## PART 2

Minimum requirements for the quality systems for the performance of pharmacovigilance activities by the licensing authority and holders

#### **Performance indicators**

**9.**—(1) The holder and the licensing authority may use performance indicators to continuously monitor the good performance of pharmacovigilance activities.

(2) The licensing authority may publish a list of performance indicators.]

**Changes to legislation:** There are currently no known outstanding effects for the The Human Medicines Regulations 2012, Paragraph 9.